Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott R Plotkin

Showing results (51-60 of 201) with videos related to

Pageof 21
Sort By:
Acta Neuropathologica|April 12, 2024
Histologic correlates of "Choroidal abnormalities" in Neurofibromatosis type 1 (NF1)Anat O Stemmer-Rachamimov, Liana Kozanno, Scott R Plotkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2025
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform NeurofibromasEva Dombi, Andrea M Gross, Brigitte C Widemann, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|April 7, 2016
Health-related Quality of Life of Individuals With Neurofibromatosis Type 2: Results From the NF2 Natural History StudyVanessa L Merker, Amanda L Bergner, Ana-Maria Vranceanu, et al.
BMC Health Services Research|August 31, 2018
Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosisVanessa L Merker, Annie Dai, Heather B Radtke, et al.
Nature Clinical Practice. Oncology|June 19, 2008
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapyScott R Plotkin, Marybeth A Singh, Caroline C O'Donnell, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|August 26, 2010
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patientsScott R Plotkin, Chris Halpin, Michael J McKenna, et al.
Journal of Neurosurgery. Spine|February 8, 2011
Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patientsScott R Plotkin, Caroline C O'Donnell, William T Curry, et al.
Neurology|July 25, 2016
Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCTAna-Maria Vranceanu, Eric Riklin, Vanessa L Merker, et al.
Patient Education and Counseling|October 14, 2020
Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosisVanessa L Merker, Scott R Plotkin, Martin P Charns, et al.
Human Molecular Genetics|September 6, 2012
Expression of SMARCB1 (INI1) mutations in familial schwannomatosisMiriam J Smith, James A Walker, Yiping Shen, et al.
Pageof 21

Showing results (51-60 of 201) with videos related to

Sort By:
Pageof 21
Acta Neuropathologica|April 12, 2024
Histologic correlates of "Choroidal abnormalities" in Neurofibromatosis type 1 (NF1)Anat O Stemmer-Rachamimov, Liana Kozanno, Scott R Plotkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2025
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform NeurofibromasEva Dombi, Andrea M Gross, Brigitte C Widemann, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|April 7, 2016
Health-related Quality of Life of Individuals With Neurofibromatosis Type 2: Results From the NF2 Natural History StudyVanessa L Merker, Amanda L Bergner, Ana-Maria Vranceanu, et al.
BMC Health Services Research|August 31, 2018
Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosisVanessa L Merker, Annie Dai, Heather B Radtke, et al.
Nature Clinical Practice. Oncology|June 19, 2008
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapyScott R Plotkin, Marybeth A Singh, Caroline C O'Donnell, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|August 26, 2010
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patientsScott R Plotkin, Chris Halpin, Michael J McKenna, et al.
Journal of Neurosurgery. Spine|February 8, 2011
Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patientsScott R Plotkin, Caroline C O'Donnell, William T Curry, et al.
Neurology|July 25, 2016
Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCTAna-Maria Vranceanu, Eric Riklin, Vanessa L Merker, et al.
Patient Education and Counseling|October 14, 2020
Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosisVanessa L Merker, Scott R Plotkin, Martin P Charns, et al.
Human Molecular Genetics|September 6, 2012
Expression of SMARCB1 (INI1) mutations in familial schwannomatosisMiriam J Smith, James A Walker, Yiping Shen, et al.
Pageof 21